INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/MASSACHUSETTS/18/2022 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN

CHEBI:CHEBI_754928

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

listing_expiration_date
20251231
dosage_form
INJECTION
route
INTRAMUSCULAR
marketing_start_date
20220701
package_marketing_start_date
20220701
product_type
VACCINE
marketing_category
BLA
labeler_name
Sanofi Pasteur Inc.
active_ingredient_name
INFLUENZA A VIRUS A/WISCONSIN/588/2019 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN
brand_name
Flublok Quadrivalent Northern Hemisphere
brand_name_base
Flublok Quadrivalent Northern Hemisphere
product_ndc
49281-722
application_number
BLA125285
spl_id
f44f01fb-1905-4ead-8d1a-7362ef09797b
active_ingredient_strength
45 ug/.5mL
package_ndc
49281-722-10
package_description
10 SYRINGE in 1 CARTON (49281-722-10) / .5 mL in 1 SYRINGE (49281-722-88)
generic_name
INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/MASSACHUSETTS/18/2022 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class